Related Experiment Video
Updated: Feb 9, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Targeting phosphatases of regenerating liver (PRLs) in cancer
Min Wei1, Konstantin V Korotkov1, Jessica S Blackburn1
1Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, United States.
Abstract:
The phosphatase of regenerating liver (PRL) family, also known as protein tyrosine phosphatase 4A (PTP4A), are dual-specificity phosphatases with largely unknown cellular functions. However, accumulating evidence indicates that PRLs are oncogenic across a broad variety of human cancers. PRLs are highly expressed in advanced tumors and metastases compared to early stage cancers or matched healthy tissue, and high expression of PRLs often correlates with poor patient prognosis. Consequentially, PRLs have been considered potential therapeutic targets in cancer. Persistent efforts have been made to define their role and mechanism in cancer progression and to create specific PRL inhibitors for basic research and drug development. However, targeting PRLs with small molecules remains challenging due to the highly conserved active site of protein tyrosine phosphatases and a high degree of sequence similarity between the PRL protein families. Here, we review the current PRL inhibitors, including the strategies used for their identification, their biological efficacy, potency, and selectivity, with a special focus on how PRL structure can inform future efforts to develop specific PRL inhibitors.
Insights
Phosphatase of regenerating liver (PRL) proteins are oncogenic and highly expressed in advanced cancers. Developing specific PRL inhibitors for cancer therapy is challenging but crucial for future drug development.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- The phosphatase of regenerating liver (PRL) family, also known as protein tyrosine phosphatase 4A (PTP4A), are dual-specificity phosphatases.
- Accumulating evidence indicates that PRLs are oncogenic across a broad variety of human cancers, with high expression correlating with poor prognosis.
Purpose of the Study:
- To review current PRL inhibitors, including strategies for their identification.
- To discuss their biological efficacy, potency, and selectivity.
- To highlight how PRL structure can inform future inhibitor development.
Main Methods:
- Literature review of current PRL inhibitors.
- Analysis of strategies for inhibitor identification.
- Evaluation of biological efficacy, potency, and selectivity data.
Main Results:
- PRLs are highly expressed in advanced tumors and metastases.
- Targeting PRLs with small molecules is challenging due to conserved active sites and sequence similarity.
- Current PRL inhibitors vary in efficacy, potency, and selectivity.
Conclusions:
- PRLs are promising therapeutic targets in cancer due to their oncogenic roles.
- Overcoming challenges in developing specific PRL inhibitors is essential for cancer drug development.
- Understanding PRL structure is key to designing more effective and selective inhibitors.
More Related Videos
Related Concept Videos
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Targeted Cancer Therapies
There are several types of targeted therapies against...
Whole Body Regeneration
Overview of Regeneration and Repair
Regeneration
All animals have varying degrees of...

